ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer
Biospace,
ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both…
ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both…
SINGAPORE, Aug. 10, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a clinical-stage…
SINGAPORE, Aug. 10, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a clinical-stage…
SINGAPORE, Aug. 10, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a clinical-stage…
GlobeNewswire 2018-08-10 SINGAPORE, Aug. 10, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a…
SINGAPORE, Aug. 10, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a clinical-stage…
SINGAPORE, Aug. 10, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a clinical-stage…
SINGAPORE, Aug. 10, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:) (TPEx:6497), a clinical-stage biopharmaceutical…
SINGAPORE, Aug. 10, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a clinical-stage…
SINGAPORE, Aug. 06, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical…